Europe's skyline looked different to Kealen Draven. Unlike the mountains and forests of his homeland, the cities here pulsed with innovation and legacy. Yet for Kealen, this new land was not just about relocation—it was about carving a future for his family while honoring Aria's roots.
He gathered his wife Astra, their sextuplets, and trusted members of the Draven clan in a sleek boardroom in Geneva. On the table were stacks of dossiers—blueprints for their first European foothold.
"We will not simply be guests here," Kealen began, his voice steady but firm. "We will build something that lasts—a foundation strong enough to stand beside Mukul's empire, but rooted in our own identity."
The Draven Medical Vision
Astra looked at him with pride, though traces of conflict still lingered in her heart. "Medicine has always been part of my path," she said softly, her hand resting over the files. "It's the bridge between my past and my present."
Kealen nodded. "Then we build from there. The Draven Group will dedicate itself to medical science, biotechnology, and pharmaceuticals. We will heal, innovate, and make our mark on this continent."
With the Raichand family's influence and the Malhotra networks behind them, Kealen had access to doors that would have otherwise taken decades to unlock. Still, he insisted on doing things with integrity.
"We will acquire," he explained, pointing at the documents, "but we will also transform. These companies we take over will not just serve profit—they will serve people. That is our promise."
Acquiring the First Foundations
Within weeks, the Draven Group made its first moves. With the backing of Raichand advisors, Kealen secured controlling stakes in Medivance Pharma in Switzerland and Novagen Laboratories in Germany. Both had been struggling with mismanagement despite strong research potential.
Where others saw risk, Kealen saw opportunity. "They have scientists, knowledge, and infrastructure. What they lack is vision," he told Astra during one late-night planning session.
Together, they began restructuring leadership, setting up a transparent research board, and redirecting resources toward advanced medicine—especially in regenerative therapies and emergency care, areas where Astra's expertise shone brightest.
The Raichand–Draven Alliance
Priya Malhotra and Suhani Raichand personally visited their new offices to oversee the partnership. Their presence gave the Draven Group legitimacy in the European market.
"You are family now," Priya told Kealen warmly, her tone carrying both encouragement and expectation. "Europe will watch you closely. Do not underestimate the weight of the Raichand name beside yours."
Kealen bowed his head slightly. "I intend not to lean on the name, but to honor it with results."
The Children's Role
Even the sextuplets were given small tasks to instill responsibility. Lyra and Selara shadowed Astra during medical board meetings, absorbing the language of science and policy. Orion and Caelis visited the labs, asking eager questions about machinery and design. Elys and Fenris spent time with the cybersecurity division, ensuring research was protected.
"They are still children," Astra said one evening, watching them scribble notes.
"Yes," Kealen replied with a smile. "But they will grow stronger by being part of the foundation we build. This is as much their inheritance as it is ours."
Kealen's Quiet Resolve
Behind his calm demeanor, Kealen carried a silent weight. He knew Mukul's empire already stretched across continents with unimaginable strength. But rather than compete, Kealen sought complement.
"Our work will support theirs," he thought privately. "While Mukul and Anaya safeguard shadows and strategy, the Draven Group will safeguard life itself."
The European press soon began to notice. Articles circulated: "The Draven Group's Swift Rise—Backed by Raichand–Malhotra Influence". Questions arose about their origins, but Kealen kept his answers simple: "We are here to build a legacy of healing."
The First Milestone
The turning point came when Novagen Laboratories announced its first breakthrough under new leadership: a regenerative compound capable of reducing recovery time for severe injuries by nearly 40%. It stunned competitors and validated the Draven Group's bold acquisitions.
That evening, Astra joined Kealen on the villa's balcony. "It feels like the first stone laid," she said softly.
Kealen looked at her, the night sky reflecting in his steady gaze. "One stone at a time, Astra. Soon, this will not just be a base—it will be a fortress of healing, one our children can be proud to inherit."
And in that moment, the Draven Group's presence in Europe no longer felt like a beginning. It felt like destiny unfolding.